Top

Published in:

Open Access 01-07-2020 | Breast Cancer | Preclinical study

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival

Authors: Chitra Joseph, Mansour Alsaleem, Nnamdi Orah, Pavan L. Narasimha, Islam M. Miligy, Sasagu Kurozumi, Ian O. Ellis, Nigel P. Mongan, Andrew R. Green, Emad A. Rakha

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Abstract

Purpose

MMP9 is a matricellular protein associated with extracellular matrix (ECM) remodelling, that promotes tumour progression, and modulates the activity of cell adhesion molecules and cytokines. This study aims to assess the prognostic value of MMP9 and its association with cytoskeletal modulators in early-stage invasive breast cancer (BC).

Methods

MMP9 expression was evaluated by immunohistochemistry using a well-characterised series of primary BC patients with long-term clinical follow-up. Association with clinicopathological factors, patient outcome and ECM remodelling BC-biomarkers were investigated. METABRIC dataset, BC-GenExMiner v4.0 and TCGA were used for the external validation of MMP9 expression. GSEA gene enrichment analyses were used to evaluate MMP9 associated pathways.

Results

MMP9 immunopositivity was observed in the stroma and cytoplasm of BC cells. Elevated MMP9 protein levels were associated with high tumour grade, high Nottingham Prognostic Index, and hormonal receptor negativity. Elevated MMP9 protein expression correlated significantly with cytokeratin 17 (Ck17), Epidermal Growth Factor Receptor (EGFR), proliferation (Ki67) biomarkers, cell surface adhesion receptor (CD44) and cell division control protein 42 (CDC42). Cytoplasmic MMP9 expression was an independent prognostic factor associated with shorter BC-specific survival. In the external validation cohorts, MMP9 expression was also associated with poor patients’ outcome. Transcriptomic analysis confirmed a positive association between MMP9 and ECM remodelling biomarkers. GSEA analysis supports MMP9 association with ECM and cytoskeletal pathways.

Conclusion

This study provides evidence for the prognostic value of MMP9 in BC. Further functional studies to decipher the role of MMP9 and its association with cytoskeletal modulators in BC progression are warranted.

Available only for authorised users

Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278(1):16–27. https://doi.org/10.1111/j.1742-4658.2010.07919.x CrossRefPubMed

Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES (2014) Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget 5(9):2736–2749. https://doi.org/10.18632/oncotarget.1932 CrossRefPubMedPubMedCentral

Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3):562–573. https://doi.org/10.1016/j.cardiores.2005.12.002 CrossRefPubMed

Christensen J, Shastri VP (2015) Matrix-metalloproteinase-9 is cleaved and activated by cathepsin K. BMC Res Notes 8:322. https://doi.org/10.1186/s13104-015-1284-8 CrossRefPubMedPubMedCentral

Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA (2004) Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Can Res 64(5):1675–1686CrossRef

Gorden DL, Fingleton B, Crawford HC, Jansen DE, Lepage M, Matrisian LM (2007) Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer 121(3):495–500. https://doi.org/10.1002/ijc.22594 CrossRefPubMed

Shi H, Wu Y, Wang Y, Zhou M, Yan S, Chen Z, Gu D, Cai Y (2015) Liquiritigenin potentiates the inhibitory effects of cisplatin on invasion and metastasis via downregulation MMP-2/9 and PI3 K/AKT signaling pathway in B16F10 melanoma cells and mice model. Nutr Cancer 67(5):761–770. https://doi.org/10.1080/01635581.2015.1037962 CrossRefPubMed

Majumder A, Ray S, Banerji A (2019) Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells. Mol Cell Biochem 452(1–2):111–121. https://doi.org/10.1007/s11010-018-3417-6 CrossRefPubMed

Cohen M, Wuillemin C, Irion O, Bischof P (2008) Regulation of MMP-9 by p53 in first trimester cytotrophoblastic cells. Hum Reprod 23(10):2273–2281. https://doi.org/10.1093/humrep/den264 CrossRefPubMedPubMedCentral

10.

Bouzahzah B, Albanese C, Ahmed F, Pixley F, Lisanti MP, Segall JD, Condeelis J, Joyce D, Minden A, Der CJ, Chan A, Symons M, Pestell RG (2001) Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med 7(12):816–830CrossRefPubMedPubMedCentral

11.

Poincloux R, Lizarraga F, Chavrier P (2009) Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 122(Pt 17):3015–3024. https://doi.org/10.1242/jcs.034561 CrossRefPubMed

12.

Gupta A, Cao W, Sadashivaiah K, Chen W, Schneider A, Chellaiah MA (2013) Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9. Sci World J 2013:493689. https://doi.org/10.1155/2013/493689 CrossRef

13.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (6871):530–536. https://doi.org/10.1038/415530a

14.

McGowan PM, Duffy MJ (2008) Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 19(9):1566–1572. https://doi.org/10.1093/annonc/mdn180 CrossRefPubMed

15.

Joseph C, Macnamara O, Craze M, Russell R, Provenzano E, Nolan CC, Diez-Rodriguez M, Sonbul SN, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Mukherjee A (2018) Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. Br J Cancer 118(8):1142–1151. https://doi.org/10.1038/s41416-018-0041-x CrossRefPubMedPubMedCentral

16.

WHO (2019) The classification of tumours editorial board: breast tumours, 5th edn. World Health Organization, IARC Press, Lyon

17.

Muftah AA, Aleskandarany MA, Al-Kaabi MM, Sonbul SN, Diez-Rodriguez M, Nolan CC, Caldas C, Ellis IO, Rakha EA, Green AR (2017) Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Res Treat 164(2):341–348. https://doi.org/10.1007/s10549-017-4270-0 CrossRefPubMedPubMedCentral

18.

Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO (2004) Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91(8):1532–1542. https://doi.org/10.1038/sj.bjc.6602184 CrossRefPubMedPubMedCentral

19.

Chrysanthou E, Gorringe KL, Joseph C, Craze M, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA, Ellis IO, Mukherjee A (2017) Phenotypic characterisation of breast cancer: the role of CDC42. Breast Cancer Res Treat 164(2):317–325. https://doi.org/10.1007/s10549-017-4267-8 CrossRefPubMedPubMedCentral

20.

Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO (2012) A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 133(3):979–995. https://doi.org/10.1007/s10549-011-1865-8 CrossRefPubMed

21.

Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122(1):45–53. https://doi.org/10.1007/s10549-009-0508-9 CrossRefPubMed

22.

Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661–671. https://doi.org/10.1002/path.1559 CrossRefPubMed

23.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel m (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223. https://doi.org/10.1093/annonc/mdt303 CrossRefPubMedPubMedCentral

24.

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Group M, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352. https://doi.org/10.1038/nature10983

25.

Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G, Campion L (2012) bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 131(3):765–775. https://doi.org/10.1007/s10549-011-1457-7 CrossRefPubMed

26.

Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. https://doi.org/10.1038/nature11412 CrossRef

27.

Joseph C, Arshad M, Kurozomi S, Althobiti M, Miligy IM, Al-Izzi S, Toss MS, Goh FQ, Johnston SJ, Martin SG, Ellis IO, Mongan NP, Green AR, Rakha EA (2019) Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Res Treat 174(2):387–399. https://doi.org/10.1007/s10549-018-05085-9 CrossRefPubMed

28.

Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350. https://doi.org/10.1002/ijc.21004 CrossRefPubMed

29.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391. https://doi.org/10.1038/sj.bjc.6602678 CrossRefPubMedPubMedCentral

30.

Lohse M, Bolger AM, Nagel A, Fernie AR, Lunn JE, Stitt M, Usadel B (2012) RobiNA: a user-friendly, integrated software solution for RNA-Seq-based transcriptomics. Nucleic Acids Res 40(Web Server issue):W622–627. https://doi.org/10.1093/nar/gks540 CrossRefPubMedPubMedCentral

31.

Wang J, Vasaikar S, Shi Z, Greer M, Zhang B (2017) WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res 45(W1):W130–W137. https://doi.org/10.1093/nar/gkx356 CrossRefPubMedPubMedCentral

32.

Zhang B, Kirov S, Snoddy J (2005) WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33(Web Server issue):W741–W748. https://doi.org/10.1093/nar/gki475 CrossRefPubMedPubMedCentral

33.

Pirooznia M, Nagarajan V, Deng Y (2007) GeneVenn—a web application for comparing gene lists using Venn diagrams. Bioinformation 1(10):420–422. https://doi.org/10.6026/97320630001420 CrossRefPubMedPubMedCentral

34.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401–404. https://doi.org/10.1158/2159-8290.CD-12-0095 CrossRefPubMed

35.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signal 6(269):l1. https://doi.org/10.1126/scisignal.2004088 CrossRef

36.

Pego ER, Fernandez I, Nunez MJ (2018) Molecular basis of the effect of MMP-9 on the prostate bone metastasis: a review. Urol Oncol 36(6):272–282. https://doi.org/10.1016/j.urolonc.2018.03.009 CrossRefPubMed

37.

Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, Chen H, Yin W, Liu J, Gu Y, Mo M, He J (2011) Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. J Surg Oncol 104(7):841–846. https://doi.org/10.1002/jso.22001 CrossRefPubMed

38.

Hu X, Li D, Zhang W, Zhou J, Tang B, Li L (2012) Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet 286(6):1537–1543. https://doi.org/10.1007/s00404-012-2456-6 CrossRefPubMed

39.

Birukova AA, Smurova K, Birukov KG, Usatyuk P, Liu F, Kaibuchi K, Ricks-Cord A, Natarajan V, Alieva I, Garcia JG, Verin AD (2004) Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho-dependent mechanisms. J Cell Physiol 201(1):55–70. https://doi.org/10.1002/jcp.20055 CrossRefPubMed

40.

Jablonska-Trypuc A, Matejczyk M, Rosochacki S (2016) Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem 31(sup1):177–183. https://doi.org/10.3109/14756366.2016.1161620 CrossRefPubMed

41.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174–183. https://doi.org/10.1016/S1470-2045(09)70262-1 CrossRefPubMed

42.

Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulinska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA (2014) Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 5(13):4603–4650. https://doi.org/10.18632/oncotarget.2209 CrossRefPubMedPubMedCentral

43.

Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ (2009) Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res 39(2):177–186. https://doi.org/10.1111/j.1872-034X.2008.00449.x CrossRefPubMed

44.

Zhang Y, Li J, Lai XN, Jiao XQ, Xiong JP, Xiong LX (2019) Focus on Cdc42 in breast cancer: new insights, target therapy development and non-coding RNAs. Cells. https://doi.org/10.3390/cells8020146 CrossRefPubMedPubMedCentral

45.

Linder S (2007) The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol 17(3):107–117. https://doi.org/10.1016/j.tcb.2007.01.002 CrossRefPubMed

46.

Weaver AM (2006) Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metas 23(2):97–105. https://doi.org/10.1007/s10585-006-9014-1 CrossRef

47.

Nascimento CF, Gama-De-Souza LN, Freitas VM, Jaeger RG (2010) Role of MMP9 on invadopodia formation in cells from adenoid cystic carcinoma. Study by laser scanning confocal microscopy. Microsc Res Tech 73(2):99–108. https://doi.org/10.1002/jemt.20761 CrossRefPubMed

48.

Nakahara H, Otani T, Sasaki T, Miura Y, Takai Y, Kogo M (2003) Involvement of Cdc42 and Rac small G proteins in invadopodia formation of RPMI7951 cells. Genes Cells 8(12):1019–1027CrossRefPubMed

49.

Desai B, Ma T, Chellaiah MA (2008) Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion. J Biol Chem 283(20):13856–13866. https://doi.org/10.1074/jbc.M709401200 CrossRefPubMedPubMedCentral

50.

Chetty C, Vanamala SK, Gondi CS, Dinh DH, Gujrati M, Rao JS (2012) MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell Signal 24(2):549–559. https://doi.org/10.1016/j.cellsig.2011.10.008 CrossRefPubMed

51.

Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ (1990) Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 8(9):1457–1465. https://doi.org/10.1200/JCO.1990.8.9.1457 CrossRefPubMed

52.

Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, Mazzocca A, Paradiso A, Quaranta M (2010) Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res 30(9):3521–3527PubMed

53.

Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10(22):7621–7628. https://doi.org/10.1158/1078-0432.CCR-04-1061 CrossRefPubMed

54.

Achen MG, Stacker SA (2008) Molecular control of lymphatic metastasis. Ann N Y Acad Sci 1131:225–234. https://doi.org/10.1196/annals.1413.020 CrossRefPubMed

55.

Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77(6):926–931. https://doi.org/10.1038/bjc.1998.153 CrossRefPubMedPubMedCentral

56.

Radisky ES, Radisky DC (2010) Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mamm Gland Biol Neoplasia 15(2):201–212. https://doi.org/10.1007/s10911-010-9177-x CrossRef

57.

Iochmann S, Blechet C, Chabot V, Saulnier A, Amini A, Gaud G, Gruel Y, Reverdiau P (2009) Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion. Clin Exp Metas 26(5):457–467. https://doi.org/10.1007/s10585-009-9245-z CrossRef

58.

Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423–1437. https://doi.org/10.1038/nm.3394 CrossRefPubMedPubMedCentral

59.

Labovsky V, Martinez LM, Davies KM, Garcia-Rivello H, Calcagno Mde L, Matas A, Fernandez Vallone VB, Wernicke A, Choi H, Chasseing NA (2015) Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells. Clin Breast Cancer 15(1):e13–21. https://doi.org/10.1016/j.clbc.2014.05.006 CrossRefPubMed

60.

Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM (2004) Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88(1):75–85. https://doi.org/10.1007/s10549-004-1200-8 CrossRefPubMed

Title: Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
Authors: Chitra Joseph
Mansour Alsaleem
Nnamdi Orah
Pavan L. Narasimha
Islam M. Miligy
Sasagu Kurozumi
Ian O. Ellis
Nigel P. Mongan
Andrew R. Green
Emad A. Rakha
Publication date: 01-07-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05670-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis

Does oncoplastic surgery increase immediate (30-day) postoperative complications? An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database

Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate

Sensory profiles in women with neuropathic pain after breast cancer surgery

Somatic mutations of triple-negative breast cancer: a comparison between Black and White women

Predictive risk factors of complications in different breast reconstruction methods

Keynote webinar | Spotlight on antibody–drug conjugates in cancer